Dynamin 2 Is Correlated with Recurrence and Poor Prognosis of Papillary Thyroid Cancer

22 August 2020: Clinical Research

Ning Ren ^1BCF* , Zhenmin Tian ^2CE* , Hongmei Sun ^3BD , Xiaofei Lu ^4ABCDEF*

DOI: 10.12659/MSM.924590

Med Sci Monit 2020; 26:e924590

Table 3 Prognostic value of dynamin 2 (DNM2) and other clinicopathological factors were evaluated by univariate and multivariate analyses.

Variables	5-year OS	P*	HR	95% CI	P**
Sex
Male	89.0	0.380
Female	86.6
Age
	88.3	0.438
≥45	93.7
Tumor size (cm)
≤2	91.4	0.905
>2	92.3
Tumor number
Single	92.7	0.681
Multiple	92.3
Differentiation
Good	92.4	0.105	1
Moderate	92.6		1.43	0.32–6.34	0.636
Site
Left or right	92.6	0.674
Left+right	91.7
T stage
I+II	95.0	0.037	1
III+IV	72.9		1.31	0.30–5.67	0.720
N stage
N0	90.7	0.009	1
N1	85.7		5.87	1.26–27.2	0.024
TNM stage
I+II	93.7	0.060
III+IV	88.4
DNM2
Low	96.7	0.004	1
High	78.5		4.82	1.46–15.92	0.010
^* Calculated by the log-rank test in univariate analysis; ^** calculated by the Cox-regression hazard model in multivariate analysis. OS – overall survival; HR – hazard ratio; CI – confidence interval; TNM – tumor-node-metastasis.